Atrial Fibrillation Vulnerability Assessed by Echocardiography as Predictor of Post-ablation Atrial Fibrillation Recurrence: Prospective Three-year Follow-up Study

• Register: ChiCTR
• Last refreshed on: 18 April 2017
• Main ID: ChiCTR-OOC-14005616
• Date of registration: 2014-10-22
• Prospective Registration: Yes
• Primary sponsor: Shandong University/Qilu Hospital
• Public title: Atrial Fibrillation Vulnerability Assessed by Echocardiography as Predictor of Post-ablation Atrial Fibrillation Recurrence: Prospective Three-year Follow-up Study
• Scientific title: Atrial Fibrillation Vulnerability Assessed by Echocardiography as Predictor of Post-ablation Atrial Fibrillation Recurrence: Prospective Three-year Follow-up Study
• Date of first enrolment: 2015-01-01
• Target sample size: Case series:200;
• Recruitment status: Pending
• URL: http://www.chictr.org.cn/showproj.aspx?proj=10008
• Study type: Observational study
• Study design: Case series
• Phase: Other

Countries of recruitment

China

Contacts

• Name: Jing-quan Zhong

• Name: Jing-quan Zhong
• Affiliation: Shandong University/Qilu Hospital

Key inclusion & exclusion criteria

Inclusion criteria: 1) Age:18-75years; 2) presence of drug-refractory symptomatic paroxysmal or persistent AF as evidenced by 12-lead electrocardiogram (ECG) and 24h Holter monitoring; 3) absence of left atrial appendage/left atrium thrombus in TEE, or coronary CT examination if TEE is not tolerated; 4) left ventricular ejection fraction more than 30%; 5) left atrial diameter less than 55mm; 6) patient undergoing RFCA; and 7) agreed to participate in this study and complete follow-up by signing informed consent.
Exclusion criteria: 1)Severe cardiomyopathy, valvular disease, congenital heart disease, decompensated heart failure and left ventricular dysfunction; 2) malignant tumors, acute or chronic infection, hyperthyroidism, connective tissue disease, liver and kidney dysfunction, poor control of blood pressure; 3) history of acute cardiovascular and cerebrovascular events, trauma or surgery within three previous months; 4) on immunosuppressive therapy and with low numbers of white blood cells; 5) reversible atrial fibrillation caused by thyroid hyperfunction, alcohol drinking, surgery or other causes; 6) failed ablation or severe post-ablation complications; 7) patient with contraindications to anti-coagulation; 8) pregnant or breast-feeding women; or 9) participation in other clinical research.

Age minimum: 18
Age maximum: 75
Gender: Both

Health Condition(s) or Problem(s) studied

atrial fibrillation

Intervention(s)

Case series:ablation;

Primary Outcome(s)

Atrial fibrillation vulnerability;

Source(s) of Monetary Support

Funded by Biosense Webster